Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Kremer, J. M.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

DRUGS AND DRUG THERAPY

Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis

Joel M. Kremer, MD

17 April 2001 | Volume 134 Issue 8 | Pages 695-706

Because of radiographic evidence of progressive bone loss and the inability to eliminate synovial proliferation with methotrexate, it became apparent that therapy for rheumatoid arthritis needed further advancement. Methotrexate is not a remission-inducing drug and may have dose-limiting toxicity. In the past 2 years, three new disease-modifying antirheumatic drugs (DMARDs) have been approved: leflunomide, etanercept, and infliximab. Each of these agents has demonstrated efficacy compared with placebo in randomized, controlled studies. Because methotrexate had a dominant therapeutic role, the new drugs were also studied in combination with it. Other established DMARDs, such as sulfasalazine and hydroxychloroquine, have also demonstrated efficacy when used together with methotrexate. The results of these combination studies clearly demonstrate that clinical responses can be meaningfully improved when new and existing DMARDs are added to methotrexate. Although toxicity remains a serious concern when powerful immune modulators and antimetabolites are used in combination, relatively few serious adverse events have been reported during 2-year treatment periods. It has also become apparent that combinations of new DMARDs and methotrexate virtually halt radiographic progression over 2 years. The new agents are expensive, but annual costs must be weighed against the personal and societal expense of joint arthroplasty, hospitalizations, disability, and diminished quality of life that accompanies poorly controlled rheumatoid arthritis. The ultimate value of combination DMARD therapy with methotrexate will be determined by long-term data on safety, efficacy, and effects on radiographic deterioration of bone. Additional long-term observational data on the incidence of joint arthroplasty and disability will help to place the issue of societal costs in a better perspective. This will allow the value of aggressive treatment to be established with certainty.

Author and Article Information

From The Center for Rheumatology, Albany, New York.

Requests for Single Reprints: Joel M. Kremer, MD, The Center for Rheumatology, 1367 Washington Avenue, Albany, NY 12206; e-mail, jkremer{at}rheum-docs.com.

This article has been cited by other articles:

				G A W Bruyn, G Tate, F Caeiro, J Maldonado-Cocco, R Westhovens, H Tannenbaum, M Bell, O Forre, O Bjorneboe, P P Tak, et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study Ann Rheum Dis, August 1, 2008; 67(8): 1090 - 1095. [Abstract] [Full Text] [PDF]

				C Prendiville, M O'Doherty, P Moriarty, and L Cassidy The use of infliximab in ocular inflammation Br. J. Ophthalmol., June 1, 2008; 92(6): 823 - 825. [Abstract] [Full Text] [PDF]

				M C Genovese, M Schiff, M Luggen, J-C Becker, R Aranda, J Teng, T Li, N Schmidely, M Le Bars, and M Dougados Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy Ann Rheum Dis, April 1, 2008; 67(4): 547 - 554. [Abstract] [Full Text] [PDF]

				R. J. Weiss, A. Ehlin, S. M. Montgomery, M. C. Wick, A. Stark, and P. Wretenberg Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54 579 Swedish RA inpatients Rheumatology, April 1, 2008; 47(4): 491 - 494. [Abstract] [Full Text] [PDF]

				L B Hughes, T M Beasley, H Patel, H K Tiwari, S L Morgan, J E Baggott, K G Saag, J McNicholl, L W Moreland, G S Alarcon, et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis Ann Rheum Dis, September 1, 2006; 65(9): 1213 - 1218. [Abstract] [Full Text] [PDF]

				G. Pomponio, L. Ghattas, and F. Mascella Surgery in rheumatoid arthritis: reply Rheumatology, June 1, 2006; 45(6): 779 - 779. [Full Text] [PDF]

				E. H. S. Choy, C. Smith, C. J. Dore, and D. L. Scott A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal Rheumatology, November 1, 2005; 44(11): 1414 - 1421. [Abstract] [Full Text] [PDF]

				M. M Reidenberg and T. Walley The pros and cons of essential medicines for rich countries BMJ, November 13, 2004; 329(7475): 1172 - 1172. [Full Text] [PDF]

				D. P. Richman and M. A. Agius Treatment of autoimmune myasthenia gravis Neurology, December 23, 2003; 61(12): 1652 - 1661. [Abstract] [Full Text] [PDF]

				I. K Nahar, K. Shojania, C. A Marra, A. H Alamgir, and A. H Anis Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease Ann. Pharmacother., September 1, 2003; 37(9): 1256 - 1265. [Abstract] [Full Text] [PDF]

				P Ranganathan, S Eisen, W M Yokoyama, and H L McLeod Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis, January 1, 2003; 62(1): 4 - 9. [Abstract] [Full Text] [PDF]

				R. Foroozan, L. M. Buono, R. C. Sergott, and P. J. Savino Retrobulbar Optic Neuritis Associated With Infliximab Arch Ophthalmol, July 1, 2002; 120(7): 985 - 987. [Full Text] [PDF]

				M C Hochberg, J K Tracy, and R H Flores ""Stepping-up"" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate Ann Rheum Dis, November 1, 2001; 60(90003): iii51 - 54. [Full Text] [PDF]

				Leflunomide for Rheumatoid Arthritis Journal Watch (General), October 19, 2001; 2001(1019): 3 - 3. [Full Text]

				A. Davidson and B. Diamond Autoimmune Diseases N. Engl. J. Med., August 2, 2001; 345(5): 340 - 350. [Full Text] [PDF]